Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 9/20 | 0.54 |
| ▸ | NPY1R | P25929 | 5/20 | 0.54 |
| ▸ | NPY2R | P49146 | 5/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.54 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.52 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31613777 | 0.94 | NPY1R (0.55) | NPY4RNPY1RNPY2RBACE1BACE2 | |
| SCHEMBL29511617 | 0.89 | NPY4R (0.54) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29530540 | 0.88 | OPRM1 (0.49) | NPY4RNPY1RNPY2RBACE1BACE2 | |
| SCHEMBL31307271 | 0.87 | BACE1 (0.54) | NPY4RNPY1RNPY2RBACE1BACE2 | |
| SCHEMBL29611448 | 0.86 | BACE1 (0.56) | NPY4RNPY1RNPY2RNPY5RBACE1 | |
| SCHEMBL31031460 | 0.86 | NPY4R (0.54) | NPY4RNPY1RNPY2RNPY5RBACE1 | |
| SCHEMBL29531082 | 0.86 | OPRM1 (0.56) | BACE1BACE2KISS1R | |
| SCHEMBL29531626 | 0.86 | OPRM1 (0.56) | BACE1BACE2KISS1R | |
| SCHEMBL31229206 | 0.86 | BACE1 (0.55) | NPY4RNPY1RNPY2RBACE1BACE2 | |
| SCHEMBL30784911 | 0.86 | BACE1 (0.55) | NPY4RNPY1RNPY2RBACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4565281-A1 | SITE-SPECIFIC MODIFICATION BY A BBB-SHUTTLE OF ANTIBODY-BASED ENTITIES FOR CROSSING THE BLOOD-BRAIN BARRIER | Gate2Brain, S.L. (ES) | 2025-06-11 | — | — | EP | disclosed |